Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study

Affiliations

• ¹ Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
• ² Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada.
• ³ Dermatology Research Institute, Calgary, AB, Canada.
• ⁴ Skin Health & Wellness Centre, Calgary, AB, Canada.
• ⁵ Probity Medical Research, Calgary, AB, Canada.
• ⁶ Queen's University, Kingston, ON, Canada.
• ⁷ SKiN Centre for Dermatology, Peterborough, ON, Canada.
• ⁸ Probity Medical Research, Peterborough, ON, Canada.
• ⁹ Clinal Immunology and Allergy, McMaster University, Hamilton, ON, Canada.
• ¹⁰ Probity Medical Research, Hamilton, ON, Canada.
• ¹¹ Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
• ¹² Section of Paediatric Dermatology, Department of Paediatric Medicine, The Hospital for Sick Children, Toronto, ON, Canada.
• ¹³ Department of Dermatology, McMaster University, Hamilton, ON, Canada.
• ¹⁴ Dermatrials Research Inc. & Venderm Innovations in Psoriasis, Hamilton, ON, Canada.
• ¹⁵ Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
• ¹⁶ Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, AB, Canada.
• ¹⁷ Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, AB, Canada.
• ¹⁸ Department of Dermatology, Women's College Hospital, Toronto, ON, Canada.
• ¹⁹ Probity Medical Research Inc, Waterloo, ON, Canada.